Heart rate variability in chronic heart failure: Target for therapy?

American Heart Journal

Volumn 146, Issue 3, 2003, Pages 385-387

  Sueta, Carla A ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EDROPHONIUM; METHACHOLINE; NORADRENALIN; OXOTREMORINE; PYRIDOSTIGMINE; SCOPOLAMINE; SODIUM;

CHOLINERGIC ACTIVITY; CHOLINERGIC STIMULATION; EDITORIAL; HEART BEAT; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HEART WORK; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RR INTERVAL; SODIUM BLOOD LEVEL; SUDDEN DEATH; SYMPATHETIC TONE; VAGUS TONE;

EID: 0041831287     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00320-X     Document Type: Editorial

References (17)

1. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995;92:3206-11.
2. Behling A, Moraes RS, Rohde LE, et al. Cholinergic stimulation with pyridastigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. Am Heart J 2003;146:494-500.
3. Pumprla J, Howorka K, Groves D, et al. Functional assessment of heart rate variability: physiological basis and practical applications. Int J Cardiol 2002;84:1-14.
4. Fauchier L, Babuty D, Cosnay P, et al. Heart rate variability in idiopathic dilated cardiomyopathy: characteristics and prognostic value. J Am Coll Cardiol 1997;30:1009-14.
5. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-Heart). Circulation 1998;98:1510-6.
6. Fauchier L, Babuty D, Cosnay P, et al. Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1999;33:1203-7.
7. Galinier M, Pathak A, Fourcade J, et al. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J 2000;21:475-82.
8. Bilchick KC, Fetics B, Djoukeng R, et al. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Triol of Antiarrhythmic Therapy in Congestive Heart Failure). Am J Cardiol 2002;90:24-8.
9. Lin J-L, Chan H-L, Du C-C, et al. Long-term beta-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. Am Heart J 1999;137:658-65.
10. Vanoli E, De Ferrari GM, Stramba-Badiale M, et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 1991;68:1471-81.
11. De Ferrari GM, Salvati P, Grossoni M, et al. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death: a study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. J Am Coll Cardiol 1993;21:283-90.
12. Martin GJ, Magid NM, Myers G, et al. Heart rate variability and sudden death secondary to coronary artery disease during ambulatory electrocardiographic monitoring. Am J Cardiol 1987;60:86-9.
13. Huikuri HV, Valkama JO, Airaksinen KEJ, et al. Frequency domain measures of heart rate variability before the onset of nonsustained and sustained ventricular tachycardia in patients with coronary artery disease. Circulation 1993;87:1220-8.
14. Bikkina M, Alpert MA, Mukerji R, et al. Diminished short-term heart rate variability predicts inducible ventricular tachycardia. Chest 1998;113:312-6.
15. Mitrani RD, Kloosterman EM, Huikuri H, et al. Muscarinic receptor stimulation with edrophonium hydrochloride does not elevate ventricular fibrillation thresholds in humans. J Cardiovasc Electrophysiol 1999;10:809-16.
16. Casadei B, Conway J, Forfar C, et al. Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure. Heart 1996;75:274-80.
17. Hull SS Jr, Vanoli E, Adamson TB, et al. Do increases in markers of vagal activity imply protection from sudden death? The case of scopolamine. Circulation 1995;91:2516-9.